NCT04160377

A Clinical Trial of Fluvoxamine for Melancholia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Lingjiang Li · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for endogenous depression. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.

Detailed description

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for melancholia. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.

Conditions

• Depressive Disorder
• Endogenous Depression
• Melancholia

Interventions

Type	Name	Description
DRUG	Fluvoxamine	Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .

Timeline

• Start date: 2019-08-01
• Primary completion: 2022-06-30
• Completion: 2022-09-30
• First posted: 2019-11-13
• Last updated: 2022-04-12

Locations

1 site across 1 country: China